Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Cabozantinib;   Drug: Atezolizumab;   Drug: Docetaxel Sponsors:   Hoffmann-La Roche;   Exelixis;   Chugai Pharmaceutical Recruiting

Source: ClinicalTrials.gov - July 15, 2020 Category: Research Source Type: clinical trials